Triple-Negative Breast Cancer Treatment |trodelvy in india

1. Triple-Negative Breast Cancer Treatment About Triple-Negative Breast Cancer (TNBC): Triple-negative breast cancer accounts for approximately 10 to 15% of all breast cancers. The term triple-negative breast cancer (TNBC) refers to the fact that the cancer cells don’t have estrogen receptors (ER) or progesterone receptors (PR) and also don’t create any or excess protein known as HER2. (The cells test "negative" on all 3 tests.) These cancers tend to be a bit more common in women aged less than 40, who are Black, or who have a BRCA1 mutation. Triple-Negative Breast Cancer differs from other kinds of invasive breast cancer in that it tends to progress and spread quickly, has limited treatment options, and tends to have a poor prognosis (outcome). Common Characteristics of Triple-Negative Breast Cancer: Triple-negative breast cancer (TNBC) is usually a bit more aggressive, difficult to treat, and more likely to recur than cancers that are HR-positive or HER2-positive. Who Gets Triple-Negative Breast Cancer: Triple-negative breast cancer (TNBC) is more common in: • women aged less than 40 • Black women

2. • women who have a BRCA1 mutation Stats: As per American Cancer Society, triple-negative breast cancer (TNBC) represents 10 percent of breast cancers overall, but around 20 percent among Black women, who are affected more than any other group. Treatments for Triple-Negative Breast Cancer: Treatments for triple-negative breast cancer may include: • surgery • chemotherapy • immunotherapy • radiation therapy Newer Treatments for Triple-Negative Breast Cancer: Currently, Keytruda (pembrolizumab) is approved by the U.S. FDA for treating unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer, along with chemotherapy. All cancers that are unresectable cannot be surgically eliminated. The Food and Drug Administration has also approved Keytruda along with chemotherapy prior to surgery, followed by Keytruda alone after surgery for treating early-stage, triple-negative breast cancer that has a high probability of coming back (recurrence). Currently, Trodelvy (sacituzumab govitecan-hziy) is approved by the Food and Drug Administration for treating previously treated, metastatic triple-negative breast cancer (TNBC). Trodelvy is supplied for injection: 180 mg lyophilized powder in single-dose vials for reconstitution for intravenous administration. The most common side effects of trodelvy 180 mg include decreased red blood cell count, feeling tired or weak, hair loss, decreased appetite, constipation, rash, and stomach-area (abdominal) pain or discomfort. Learn more about Keytruda and Trodelvy Price/Cost, Availability & Buying Procedure: If you are looking to buy trodelvy 200 mg injection online at lowest prices, then Indian Pharma Network (IPN) can be your one-stop solution. IPN is a top-most supplier, exporter, retailer and wholesaler of generic & branded prescription medicines, which provide trodelvy 180 mg at best price in India. Please contact at TOLL-FREE: 1800-889-1064 or send your enquiry at info@indianpharmanetwork.in to find the best trodelvy 180 mg price in India. We are well-known in the pharmaceutical industry for our best quality service, immense/vast industry experience, market credentials, precise/on-time delivery, and good financial existence. At Indian Pharma Network (IPN), our tie-ups and sourcing from the most reputed brands helps enable us to offer the best trodelvy price in India. Source - https://indianpharmanetwork.mystrikingly.com/blog/triple-negative-breast-cancer-treatment